Legacy 4(1H)-quinolone scaffolds activity against acute and chronic Toxoplasma gondii infection

This study demonstrates that the legacy 4(1H)-quinolone ICI 56,780 effectively targets both acute and chronic stages of *Toxoplasma gondii* by inhibiting mitochondrial electron transport, thereby reducing parasite viability and brain cyst burden in mice despite some pharmacokinetic limitations.

The Gist

Imagine your body is a bustling city, and Toxoplasma gondii is a sneaky, microscopic burglar. This burglar has two distinct modes of operation:

1. The "Sprint" Mode (Acute Infection): When the burglar first breaks in, they run around wildly, smashing windows and causing chaos. This is the tachyzoite stage. It's fast, destructive, and easy to spot.
2. The "Hideout" Mode (Chronic Infection): Once the city's police (your immune system) show up, the burglar doesn't leave. Instead, they build a secret, fortified bunker inside your brain and muscles. They slow down, put on a disguise, and wait. This is the bradyzoite stage. They can stay in these bunkers for your entire life. If your immune system ever gets weak, the burglar wakes up and starts the chaos again.

The Problem:
Current medicines are like a police raid that works great on the sprinting burglar but fails completely against the ones hiding in the bunkers. They can't break down the bunker walls. Once the infection goes chronic, it's essentially a life sentence.

The New Solution:
This paper introduces two old, forgotten weapons (chemical compounds called 4(1H)-quinolones) that might be the key to finally clearing out these bunkers. The researchers tested two specific "keys": ICI 56,780 and WR 243246.

How Do These Weapons Work?

Think of the burglar's cell as a house with a power plant (the mitochondrion). This power plant runs on a specific type of fuel line (the electron transport chain) to keep the lights on and the burglar alive.

• The Old Weapon (Atovaquone): The current best drug, Atovaquone, tries to cut the fuel line at a specific spot. But the burglar is smart; they can mutate their fuel line to bypass this cut, making the drug useless.
• The New Keys: The researchers found that ICI 56,780 and WR 243246 attack the power plant at a different spot on the fuel line.
  • They don't just cut the line; they effectively short-circuit the entire power grid.
  • This causes the burglar's "battery" (mitochondrial membrane potential) to die instantly.
  • Because they hit a different spot, the burglar's usual tricks to resist the old drug don't work here. Even the "super-burglars" (drug-resistant strains) are helpless against these new keys.

The Results: A Tale of Two Keys

The researchers tested these keys in the lab and in mice, and the results were a mix of "Amazing" and "Okay, but needs work."

1. The Star Performer: ICI 56,780

• In the Lab: It was a superhero. It killed the sprinting burglars (tachyzoites) at incredibly low doses (nanomolar range). It also smashed the bunkers, killing the sleeping burglars (bradyzoites) effectively.
• In Mice: When they gave this drug to mice with a lethal infection, 100% of the mice survived.
• The Chronic Test: This is the big win. In mice with long-term infections (bunkers in their brains), this drug reduced the number of bunkers by up to 90%. It was far better than the current standard drug, Atovaquone, which only cleared about 60%.
• Safety: It didn't hurt the mice's own cells at the doses needed to kill the parasite.

2. The Runner-Up: WR 243246

• In the Lab: It worked well against the sprinting burglars, but it was a bit clumsy against the sleeping ones.
• In Mice: It struggled. Even at high doses, it couldn't save the mice from the lethal infection. It seems this key gets stuck or dissolves too quickly in the body (poor solubility and stability) to reach the target effectively.

Why This Matters

For decades, scientists have been stuck with treatments that only manage the acute phase of Toxoplasmosis. We have no cure for the chronic stage, meaning millions of people carry this parasite for life, risking reactivation if they get sick or immunosuppressed.

This paper suggests that ICI 56,780 is a "golden ticket." It proves that we can target the parasite's power plant in a way that kills both the active and the dormant forms.

The Catch:
Like many old keys, ICI 56,780 isn't perfect yet. It doesn't dissolve well in water (it's oily), which makes it hard to deliver as a pill. However, the researchers say this is just the starting point. Now that they know this specific shape works so well, chemists can tweak the molecule to make it easier to swallow and more stable in the body, turning this "legacy" key into a modern, life-saving cure.

In short: The researchers found an old, rusty key that turns out to be the perfect shape to unlock the door to a cure for chronic Toxoplasmosis. They just need to polish it up a bit before it's ready for the pharmacy shelf.

Technical Summary

1. Problem Statement

Toxoplasma gondii is a ubiquitous protozoan parasite causing severe disease in immunocompromised individuals and fetuses. The infection has two distinct stages:

• Acute Stage (Tachyzoites): Fast-replicating form causing tissue destruction.
• Chronic Stage (Bradyzoites): Slow-growing form residing within tissue cysts (primarily in the brain and muscle), which can persist for life and reactivate upon immunosuppression.

Current Limitations:

• Existing treatments (e.g., pyrimethamine-sulfadiazine) are effective against tachyzoites but have minimal to no activity against bradyzoites.
• Atovaquone (ATQ), the only other clinically approved drug, targets the mitochondrial electron transport chain (ETC) but fails to completely eliminate tissue cysts in chronic infections.
• There is a critical need for new chemotypes that can effectively target both acute and chronic stages, particularly those capable of overcoming ATQ resistance mechanisms.

2. Methodology

The study evaluated two "legacy" 4(1H)-quinolone compounds: ICI 56,780 and WR 243246. These compounds were previously known to inhibit the Plasmodium falciparum bc1 complex.

Experimental Approach:

• In Vitro Proliferation Assays: Tested against wild-type T. gondii (Type I RH and Type II ME49) and two ATQ-resistant (ATQR) strains (R4 and R5) to determine EC₅₀ values.
• Mechanism of Action (MOA) Studies:
  • Cytochrome c Reduction Assay: Measured inhibition of Complex II and III activity in mitochondrial fractions.
  • Mitochondrial Membrane Potential ($\Delta\Psi_m$): Used Safranin O fluorescence in digitonin-permeabilized parasites to assess depolarization.
  • Host Toxicity: Evaluated mitochondrial membrane potential in mammalian hTERT fibroblasts and cytotoxicity in HFF and BV-2 cells.
• Physicochemical Profiling: Assessed aqueous solubility, LogD, plasma protein binding, and metabolic stability (using human liver microsomes and rat hepatocytes).
• Bradyzoite Activity:
  • In Vitro: Differentiated ME49 tachyzoites into bradyzoites using Compound 1 and low CO₂. Assessed cyst size (DBA/BAG1 staining) and viability (plaque assay after mechanical/pepsin lysis).
  • Ex Vivo: Isolated bradyzoites from chronically infected mouse brains to test viability and growth inhibition.
• In Vivo Models:
  • Acute Model: Swiss Webster mice infected with RH-RFP tachyzoites; treated with compounds to monitor survival and weight.
  • Chronic Model: CBA/j and Swiss Webster mice infected with ME49-RFP; treated for 16 days post-chronic establishment; brains harvested to enumerate cyst burden.

3. Key Contributions

• Validation of Legacy Scaffolds: Demonstrated that historical 4(1H)-quinolones, previously abandoned for malaria due to solubility/resistance issues, possess potent, broad-spectrum activity against T. gondii.
• Novel Mechanism of Action: Provided evidence that ICI 56,780 and WR 243246 target the mitochondrial bc1 complex at a site distinct from ATQ, as they retain full efficacy against ATQ-resistant strains.
• Dual-Stage Efficacy: Identified ICI 56,780 as a rare compound capable of potently killing both tachyzoites and bradyzoites (both in vitro and in vivo-derived).
• Physicochemical Benchmarking: Highlighted the specific metabolic and solubility liabilities of these legacy compounds, providing a clear roadmap for future medicinal chemistry optimization.

4. Key Results

A. Potency and Resistance Profile

• ICI 56,780: Exhibited sub-nanomolar potency against wild-type RH tachyzoites (EC₅₀ = 0.34 nM) and retained high potency against ATQR strains (EC₅₀ ~1.7–2.2 nM).
• WR 243246: Effective against wild-type (EC₅₀ = 24.2 nM) and ATQR strains, but less potent than ICI 56,780.
• ATQ Comparison: ATQ showed high potency against wild-type (14.1 nM) but lost efficacy against ATQR strains (EC₅₀ > 1 µM).

B. Mechanism of Action

• Both compounds inhibited cytochrome c reduction and collapsed mitochondrial membrane potential in parasites, similar to ATQ.
• Crucial Finding: In ATQR strains, ATQ failed to depolarize mitochondria, whereas ICI 56,780 and WR 243246 remained fully effective. This confirms they bind to a different site on the bc1 complex (likely distinct from the Qo site targeted by ATQ).
• Selectivity: No significant toxicity to host mitochondria at therapeutic concentrations (up to 1 µM); toxicity only observed at high concentrations (5 µM).

C. Bradyzoite Activity

• In Vitro: Both compounds reduced cyst size and viability. ICI 56,780 showed an EC₅₀ of ~3.9 nM against bradyzoite viability.
• Ex Vivo (Mouse-derived): ICI 56,780 maintained high potency (EC₅₀ = 3.92 nM) against in vivo-derived bradyzoites. In contrast, WR 243246 showed a dramatic loss of potency against in vivo bradyzoites (EC₅₀ = 1271 nM), suggesting species-specific metabolic instability or poor bioavailability.

D. In Vivo Efficacy

• Acute Infection: ICI 56,780 provided 100% protection in mice at 10 mg/kg/day (and significant protection at 1 mg/kg/day). WR 243246 failed to protect mice even at high doses (up to 20 mg/kg), likely due to poor bioavailability.
• Chronic Infection: ICI 56,780 significantly reduced brain cyst burden in chronically infected mice:
  • 77.7% reduction at 1 mg/kg/day.
  • 89.9% reduction at 5 mg/kg/day.
  • This outperformed ATQ (59.5% reduction at 5 mg/kg/day).

E. Physicochemical Properties

• ICI 56,780: High LogD (4.85), poor aqueous solubility (<2 µM), but excellent metabolic stability in both human and rat systems.
• WR 243246: Moderate LogD (3.5), extremely low solubility, and species-specific instability (rapid clearance in rat hepatocytes, half-life <2 min), explaining its poor in vivo performance.

5. Significance

• Therapeutic Potential: ICI 56,780 represents a promising lead scaffold for a new class of anti-toxoplasmosis drugs capable of sterilizing chronic infections by eliminating tissue cysts, a major unmet medical need.
• Resistance Management: The ability of ICI 56,780 to bypass ATQ resistance mechanisms suggests it could be effective in patients failing current therapies or in regions where resistance is emerging.
• Drug Development Pathway: While ICI 56,780 shows exceptional biological activity, its poor solubility and pharmacokinetic profile necessitate medicinal chemistry optimization (e.g., improving solubility without losing potency) to advance it toward clinical use.
• Target Validation: The study reinforces the mitochondrial electron transport chain as a viable and essential target for both acute and chronic stages of T. gondii, validating the strategy of targeting bradyzoite metabolism.

In conclusion, this study successfully repurposes legacy quinolones, identifying ICI 56,780 as a potent, broad-spectrum anti-toxoplasmosis agent with a unique mechanism of action that overcomes current drug resistance, offering a strong foundation for the development of next-generation therapies for chronic toxoplasmosis.